PURPOSE: Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care. PATIENTS AND METHODS: We studied 623 consecutive ALL myeloablative HCT (1980 to 2005). Donors were autologous (n = 209), related (RD; n = 245), unrelated (URD; n = 100), and umbilical cord blood (UCB; n = 69). RESULTS: After median of 8.3 years of follow-up, 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 29% (95% CI, 26% to 32%), 26% (95% CI, 23% to 29%), and 43% (95% CI, 39% to 47%), respectively. Treatment-related mortality (TRM) at 2 years was 28% (95% CI, 25% to 31%). Mismatched URD sources yielded higher TRM (relative risk [RR], 2.2; P < .01) and lower OS (RR, 1.5; P = .05) than RD or UCB HCT. Autografting yielded significantly more relapse (68%; 95% CI, 59% to 77%; P < .01) and poorer LFS (14%; 95% CI, 10% to 18%; P = .01). HCT in first complete remission (CR1) yielded significantly better outcomes than later HCT. In a 1990 to 2005 allogeneic CR1/second complete response cohort, 5-year OS, LFS, and relapse rates were 41% (95% CI, 35% to 47%), 38% (95% CI, 32% to 44%), and 25% (95% CI, 19% to 31%), respectively; 2-year TRM was 34% (95% CI, 28% to 40%). With RD, well-matched URD and UCB sources, 5-year LFS was 40% (95% CI, 31% to 49%), 42% (95% CI, 14% to 70%), and 49% (95% CI, 34% to 64%), respectively, while relapse was 31% (95% CI, 22% to 40%), 17% (95% CI, 0% to 37%), and 27% (95% CI, 13% to 41%). Acute graft-versus-host disease was associated with fewer relapses. Since 1995, we noted progressive improvements in OS, LFS, and TRM. CONCLUSION: Allogeneic, but not autologous, HCT for ALL results in durable LFS. Importantly, HCT using UCB led to similar outcomes as either RD or well-matched URD. HCT in early remission can best exploit the potent antileukemic efficacy of allografting from UCB, RD, or URD sources.
PURPOSE: Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care. PATIENTS AND METHODS: We studied 623 consecutive ALL myeloablative HCT (1980 to 2005). Donors were autologous (n = 209), related (RD; n = 245), unrelated (URD; n = 100), and umbilical cord blood (UCB; n = 69). RESULTS: After median of 8.3 years of follow-up, 5-year overall survival (OS), leukemia-free survival (LFS), and relapse were 29% (95% CI, 26% to 32%), 26% (95% CI, 23% to 29%), and 43% (95% CI, 39% to 47%), respectively. Treatment-related mortality (TRM) at 2 years was 28% (95% CI, 25% to 31%). Mismatched URD sources yielded higher TRM (relative risk [RR], 2.2; P < .01) and lower OS (RR, 1.5; P = .05) than RD or UCB HCT. Autografting yielded significantly more relapse (68%; 95% CI, 59% to 77%; P < .01) and poorer LFS (14%; 95% CI, 10% to 18%; P = .01). HCT in first complete remission (CR1) yielded significantly better outcomes than later HCT. In a 1990 to 2005 allogeneic CR1/second complete response cohort, 5-year OS, LFS, and relapse rates were 41% (95% CI, 35% to 47%), 38% (95% CI, 32% to 44%), and 25% (95% CI, 19% to 31%), respectively; 2-year TRM was 34% (95% CI, 28% to 40%). With RD, well-matched URD and UCB sources, 5-year LFS was 40% (95% CI, 31% to 49%), 42% (95% CI, 14% to 70%), and 49% (95% CI, 34% to 64%), respectively, while relapse was 31% (95% CI, 22% to 40%), 17% (95% CI, 0% to 37%), and 27% (95% CI, 13% to 41%). Acute graft-versus-host disease was associated with fewer relapses. Since 1995, we noted progressive improvements in OS, LFS, and TRM. CONCLUSION: Allogeneic, but not autologous, HCT for ALL results in durable LFS. Importantly, HCT using UCB led to similar outcomes as either RD or well-matched URD. HCT in early remission can best exploit the potent antileukemic efficacy of allografting from UCB, RD, or URD sources.
Authors: O Ringdén; M Labopin; E Gluckman; J M Hows; B A Bradley; H J Kolb; L Fouillard; N Jacobsen; J P Vernant; F Witz; J L Harousseau; N C Gorin Journal: Bone Marrow Transplant Date: 1997-05 Impact factor: 5.483
Authors: Kenneth Cornetta; Mary Laughlin; Shelly Carter; Donna Wall; Joel Weinthal; Colleen Delaney; John Wagner; Robert Sweetman; Philip McCarthy; Nelson Chao Journal: Biol Blood Marrow Transplant Date: 2005-02 Impact factor: 5.742
Authors: Daniel Weisdorf; Michael Bishop; Bernie Dharan; Brian Bolwell; Jean Yves Cahn; Mitchell Cairo; Sergio Giralt; John Klein; Hillard Lazarus; Mark Litzow; David Marks; Philip McCarthy; Carole Miller; Gustavo Milone; James Russell; Kirk R Schultz; Jorge Sierra; Peter Wiernik; Armand Keating; Fausto Loberiza; Craig Kollman; Mary Horowitz Journal: Biol Blood Marrow Transplant Date: 2002 Impact factor: 5.742
Authors: John E Wagner; Juliet N Barker; Todd E DeFor; K Scott Baker; Bruce R Blazar; Cindy Eide; Anne Goldman; John Kersey; William Krivit; Margaret L MacMillan; Paul J Orchard; Charles Peters; Daniel J Weisdorf; Norma K C Ramsay; Stella M Davies Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: Michael G Kiehl; Ludwig Kraut; Rainer Schwerdtfeger; Bernd Hertenstein; Mats Remberger; Nicolaus Kroeger; Mathias Stelljes; Martin Bornhaeuser; Hans Martin; Christoph Scheid; Arnold Ganser; Axel R Zander; Joachim Kienast; Gerhard Ehninger; Dieter Hoelzer; Volker Diehl; Axel A Fauser; Olle Ringden Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: J H Kersey; D Weisdorf; M E Nesbit; T W LeBien; W G Woods; P B McGlave; T Kim; D A Vallera; A I Goldman; B Bostrom Journal: N Engl J Med Date: 1987-08-20 Impact factor: 91.245
Authors: Juliet N Barker; Daniel J Weisdorf; Todd E DeFor; Bruce R Blazar; Philip B McGlave; Jeffrey S Miller; Catherine M Verfaillie; John E Wagner Journal: Blood Date: 2004-10-05 Impact factor: 22.113
Authors: L Tucunduva; A Ruggeri; G Sanz; S Furst; G Socié; M Michallet; W Arcese; N Milpied; I Yakoub-Agha; W Linkesch; J Cornelissen; L Mannone; A P Iori; J-M Ribera; J Sanz; P Montesinos; D Purtill; M Labopin; E Gluckman; M Mohty; V Rocha Journal: Bone Marrow Transplant Date: 2014-07 Impact factor: 5.483
Authors: Veronika Bachanova; Michael J Burke; Sophia Yohe; Qing Cao; Karamjeet Sandhu; Timothy P Singleton; Claudio G Brunstein; John E Wagner; Michael R Verneris; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2012-03-16 Impact factor: 5.742
Authors: Steven Z Pavletic; Shaji Kumar; Mohamad Mohty; Marcos de Lima; James M Foran; Marcelo Pasquini; Mei-Jie Zhang; Sergio Giralt; Michael R Bishop; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2010-04-24 Impact factor: 5.742
Authors: Michiko Ichii; Kenji Oritani; Takafumi Yokota; Qingzhao Zhang; Karla P Garrett; Yuzuru Kanakura; Paul W Kincade Journal: PLoS One Date: 2010-09-23 Impact factor: 3.240
Authors: José Luis Piñana; Jaime Sanz; Alessandra Picardi; Christelle Ferrá; Rodrigo Martino; Pere Barba; Marta Gonzalez-Vicent; María Jesús Pascual; Carmen Martín; Amparo Verdeguer; Cristina Diaz de Heredia; Pau Montesinos; José-María Ribera; Miguel Sanz; William Arcese; Guillermo Sanz Journal: Haematologica Date: 2013-10-04 Impact factor: 9.941